Table 1 |
|||||
|
Patient characteristics |
|||||
| Parameter |
Group |
Baseline |
Time point 2 |
Time point 3 |
Time point 4 |
|
|
|||||
| CD4 countsc |
SRa |
820 (800–1050) |
880 (800–960) |
1050 (978–1228) |
1000 (825–1145) |
| TRb |
560 (480–720) |
705 (588–887) |
673 (557–835) |
782 (627–903) |
|
| CD8 countsc |
SRa |
950 (780–1140) |
1029 (828–1175) |
824 (705–960) |
890 (675–992) |
| TRb |
1200 (1040–1300) |
915 (819–979) |
969 (880–1062) |
918 (862–967) |
|
| Viral loadd |
SRa |
3 BDL (169841–750000) |
4 BDL (624, 931) |
5 BDL (810) |
6 BDL |
| TRb |
3 BDL (2500–58292) |
4 BDL (1340, 95280) |
3 BDL (1300–8146) |
1 BDL (390–180991) |
|
|
|
|||||
|
a SR: sustained responder group. b TR: transient responder group. c CD4 and CD8 counts were median (first quartile-third quartile), expressed as cell numbers per μl blood. d Viral load shows the number of patients with below detectable level (BDL) of virus; also shown, in brackets, are the HIV-1 copy numbers/ml for the viremic patients, with a range of the HIV-1 copy numbers shown for groups with more than 2 viremic patients. |
|||||
|
Wu et al. Retrovirology 2008 5:24 doi:10.1186/1742-4690-5-24 |
|||||
